AVATAR-AF
Trial Details
- Trial statusRecruiting
- Study email contactavatar@imperial.ac.uk
- Chief InvestigatorDr Prapa Kanagaratnam
- Project managerDr Thiagarajah Sasikaran
- SponsorImperial College London
- Phase3
- View clinicaltrials.gov website
- View Trial Locations
Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes from Recurrent Atrial Fibrillation
Design and Objective
This study will help to determine if Atrial Fibrillation ablation without electrophysiological confirmation of pulmonary vein isolation is more effective than anti-arrhythmic agents at achieving freedom from hospital based treatment. We aim to recruit 321 patients to this study from 10 different hospitals in UK.
Key inclusion criteria
1. Documented paroxysmal atrial fibrillation 2. Modification or initiation of anti-arrhythmic agent required for symptom control 3. Males or females eighteen (18) to eighty (80) years of age. 4. Suitable candidate for catheter ablation 5. Signed informed consent